Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Castle Biosciences, Inc. - Common stock
(NQ:
CSTL
)
34.23
-0.19 (-0.55%)
Delayed Quote
Updated: 2:08 PM EST, Nov 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Castle Biosciences, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
March 13, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 09, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
March 04, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
March 03, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
February 26, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
February 19, 2026
Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported...
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
February 05, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
January 14, 2026
Via
AB Newswire
Topics
Intellectual Property
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
January 11, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
December 17, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
December 12, 2025
Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
December 09, 2025
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
November 17, 2025
Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
November 14, 2025
Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor...
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
November 11, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Reports Third Quarter 2025 Results
November 03, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
November 03, 2025
Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapies
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Participate in Upcoming Investor Conferences
October 28, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
October 26, 2025
Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high...
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
October 24, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
October 13, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
October 01, 2025
Maetzold recognized among 586 applicants to The CEO Magazine’s 2025 Executive of the Year Awards — United States program
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
September 23, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
September 17, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
September 09, 2025
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated...
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
August 25, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Participate in Upcoming Investor Conferences
August 21, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Reports Second Quarter 2025 Results
August 04, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
July 29, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
